Evidence map›Paper›PMID 36685558›Full record

ArticleFrontiers in immunology2022

Increased Myosin light chain 9 expression during Kawasaki disease vasculitis.

Hironobu Kobayashi, Motoko Y Kimura, Ichita Hasegawa, Eisuke Suganuma, Yuzuru Ikehara, Kazuhiko Azuma, Toshihiro Ito, Ryota Ebata, Yosuke Kurashima, Yohei Kawasaki and 9 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Differentiation of Cytotoxic CD8Cancer science · 2025
    Review
  4. Article
  5. Article
  6. Review
  7. Metabolomic profiling of human bladder tissue extracts.Metabolomics : Official journal of the Metabolomic Society · 2024
    Article
  8. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 2 countries.

Hironobu KobayashiDepartment of Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Motoko Y KimuraDepartment of Experimental Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Ichita HasegawaDepartment of Experimental Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Eisuke SuganumaDivision of Infectious Diseases and Immunology, Allergy, Saitama Children's Medical Center, Saitama, Japan.
Yuzuru IkeharaDepartment of Molecular and Tumor Pathology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Kazuhiko AzumaDepartment of Molecular and Tumor Pathology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Toshihiro ItoDepartment of Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Ryota EbataDepartment of Pediatrics, Graduate School of Medicine, Chiba University, Chiba, Japan.
Yosuke KurashimaDepartment of Innovative Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan.
Yohei KawasakiClinical Research Center, Chiba University Hospital, Chiba, Japan.
Yuki ShikoClinical Research Center, Chiba University Hospital, Chiba, Japan.
Naoki SaitoDepartment of Legal Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan.
Hirotaro IwaseDepartment of Legal Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan.
Youngho LeeDepartment of Pediatrics, Division of Infectious Diseases and Immunology, Guerin Children's at Cedars-Sinai Medical Center, Los Angeles, CA, United States.
Magali Noval RivasDepartment of Pediatrics, Division of Infectious Diseases and Immunology, Guerin Children's at Cedars-Sinai Medical Center, Los Angeles, CA, United States.
Moshe ArditiDepartment of Pediatrics, Division of Infectious Diseases and Immunology, Guerin Children's at Cedars-Sinai Medical Center, Los Angeles, CA, United States.
Masahiko ZukaDepartment of Forensic Medicine and Pathology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.
Hiromichi HamadaDepartment of Pediatrics, Graduate School of Medicine, Chiba University, Chiba, Japan.
Toshinori NakayamaDepartment of Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Chiba University · JPCedars-Sinai Medical Center · USChiba University Hospital · JPJapan Agency for Medical Research and Development · JPKanazawa University · JPSaitama Children's Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Kawasaki disease (KD) is an acute systemic vasculitis that predominantly afflicts children. KD development is known to be associated with an aberrant immune response and abnormal platelet activation, however its etiology is still largely unknown. Myosin light chain 9 (Myl9) is known to regulate cellular contractility of both non-muscle and smooth muscle cells, and can be released from platelets, whereas any relations of Myl9 expression to KD vasculitis have not been examined. Methods: Plasma Myl9 concentrations in KD patients and children with febrile illness were measured and associated with KD clinical course and prognosis. Myl9 release from platelets in KD patients was also evaluated in vitro. Myl9 expression was determined in coronary arteries from Lactobacillus casei cell wall extract (LCWE)-injected mice that develop experimental KD vasculitis, as well as in cardiac tissues obtained at autopsy from KD patients. Results and discussion: Plasma Myl9 levels were significantly higher in KD patients during the acute phase compared with healthy controls or patients with other febrile illnesses, declined following IVIG therapy in IVIG-responders but not in non-responders. In vitro, platelets from KD patients released Myl9 independently of thrombin stimulation. In the LCWE-injected mice, Myl9 was detected in cardiac tissue at an early stage before inflammatory cell infiltration was observed. In tissues obtained at autopsy from KD patients, the highest Myl9 expression was observed in thrombi during the acute phase and in the intima and adventitia of coronary arteries during the chronic phase. Thus, our studies show that Myl9 expression is significantly increased during KD vasculitis and that Myl9 levels may be a useful biomarker to estimate inflammation and IVIG responsiveness to KD.

Indexed as

Mucocutaneous Lymph Node SyndromeVasculitisAnimalsImmunoglobulins, IntravenousInflammationMiceMyosin Light ChainsImmunoglobulins, IntravenousMyosin Light ChainsCD69childrencoronary arteryKawasaki diseaseMyl9plateletvasculitis

Identifiers

PMID36685558
PMCPMC9853906
OpenAlexW4317781049

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.